Results 141 to 150 of about 8,703 (161)
Some of the next articles are maybe not open access.
Echinocandin Resistance in Candida Species: a Review of Recent Developments
Current Infectious Disease Reports, 2016The echinocandins are important agents for the treatment of invasive fungal infections, especially those caused by Candida species. However, as with other antimicrobial agents, microbiologic resistance to this class of antifungal agents has emerged and can result in clinical failure.
Nathan Wiederhold, Wiederhold Nathan P
exaly +3 more sources
Molecular Detection of Resistance to Echinocandins
2016In the last years, life-threatening fungal diseases have increased significantly, due to the rising number of human individuals susceptible to fungal infections, which are in part complicated by the emergence of antifungal drug-resistant pathogens.
Posteraro, Brunella +3 more
openaire +2 more sources
Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins
Mycopathologia, 2016The naturally high minimum inhibitory concentration exhibited by echinocandins against Candida parapsilosis has been known since the first introduction of these antifungal agents. Despite this awareness, clinical failures have not been reported; consequently, the resistance of C. parapsilosis to echinocandins remains unexplored.
Francieli, Chassot +6 more
openaire +2 more sources
Echinocandin resistance in human pathogenic fungi
Expert Review of Anti-infective Therapy, 2012Immunocompromised patients are at risk of developing invasive fungal infections that have mortality rates ranging from 30 to 90%.
openaire +2 more sources
Diagnostic Microbiology and Infectious Disease, 2015
MGCD290, a Hos2 fungal histone deacetylase inhibitor, showed modest activity when tested alone (MIC range, 0.12-4 μg/mL; MIC50/90, 0.5/4 μg/mL) against Candida glabrata (n=15; 14 fks mutants; 5 also fluconazole resistant), Candida albicans (8 fks mutants; 2 also fluconazole resistant), Candida tropicalis (4 fks mutants), and Candida krusei (3 fks ...
M A, Pfaller +3 more
openaire +2 more sources
MGCD290, a Hos2 fungal histone deacetylase inhibitor, showed modest activity when tested alone (MIC range, 0.12-4 μg/mL; MIC50/90, 0.5/4 μg/mL) against Candida glabrata (n=15; 14 fks mutants; 5 also fluconazole resistant), Candida albicans (8 fks mutants; 2 also fluconazole resistant), Candida tropicalis (4 fks mutants), and Candida krusei (3 fks ...
M A, Pfaller +3 more
openaire +2 more sources
Echinocandin Antifungal Drug Resistance in Candida Species: A Cause for Concern?
Current Infectious Disease Reports, 2010The echinocandins, the newest generation of antifungal agents, are inhibitors of β-1,3-D-glucan synthesis, an action that damages fungal cell walls. Despite a relatively broad spectrum of activity, these drugs are rapidly fungicidal against most Candida spp and have established noninferiority over existing antifungal drugs in the treatment of invasive ...
Sanguinetti, Maurizio +2 more
openaire +4 more sources
Echinocandin-Resistant Candida: Molecular Methods and Phenotypes
Current Fungal Infection Reports, 2011We now have a decade of experience with echinocandin drugs. Large-scale epidemiologic antifungal surveillance studies have demonstrated that caspofungin, micafungin, and anidulafungin retain high potency on clinical isolates of Candida, and resistance remains relatively low.
openaire +1 more source
Echinocandin-resistant Candida albicans: A case report from Japan
Journal of Infection and ChemotherapyEchinocandin-resistant Candida albicans (C. albicans) is a rare but increasing global concern. In Japan, at least three cases had been confirmed by the end of 2015. Mutations in FKS cause echinocandin resistance in Candida species, which is primarily driven by previous echinocandin antifungal use. C.
Sayaka Hikida +12 more
openaire +2 more sources